The way forward, then, is to deliver truly personalised medicines and care. For industry, this means developing therapies ...

The data from the real-world evidence study "Characterizing uncontrolled severe asthma in Canada (ALERT)" was recently ...

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

The global atorvastatin calcium market is experiencing growth due to an increase in the cardiovascular disease population and the availability of generic products is expected to drive the growth of ...

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

GlaxoSmithKline Pharma is shifting focus to specialty treatments and preventive healthcare, emphasizing adult vaccines and ...

PHILADELPHIA, PA, USA I October 08, 2024 I GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III ...

ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries: London, UK Wednesday, October 9, 2024, 12:00 Hrs [IST] GSK plc announced that ...